A Case Study Of Tasly Group Of Globalization And R&D And Innovation

Since the reform and opening up,China's pharmaceutical industry has developed rapidly and its important position in China's social and economic development has become increasingly prominent.In recent years,the overseas M&A events in China's pharmaceutical industry have continued to grow,whose main purpose is to acquire overseas advanced technologies and promote domestic R&D innovation.China's pharmaceutical manufacturing industry has insufficient investment in R&D,and small number of R&D personnel has become the norm in the industry.The low innovation capacity of China's pharmaceutical industry,the problem of financing constraints and insufficient products R&D capabilities have hindered the development of China's pharmaceutical industry.R&D and innovation activities in the pharmaceutical industry last for a long time and have high risks,which are bound to be subject to strong financing constraints.Financing constraints further inhibited the company's investment in R&D innovation activities.Internationalization provides an effective way for Chinese pharmaceutical manufacturing enterprises to promote R&D and innovation.It can acquire advanced technology through direct investment in enterprises in developed countries,and transfer technology to China through international networks to promote R&D and innovation in the home country.On the other hand,in the practice of China's pharmaceutical companies overseas' M&A,products can go abroad and expand overseas sales to obtain foreign exchange income.Collaboration with overseas companies for clinical research can share domestic R&D expenses and risks,then alleviate financing constraints from different degrees.As a traditional medical industry in China,Chinese medicine is highly valued by the government and people of China.It will become an important task for Chinese medicine manufacturing enterprises to realize industrial modernization and internationalization of traditional Chinese medicine that represents China's traditional culture.In fact,a group of traditional Chinese medicine manufacturers with an international strategic vision began the road of overseas investment and overseas certification in the early 20 th century.When Tasly was listed in 2002,it proposed the development strategy of "Chinese medicine internationalization" and began the road of international development.In the process of international development,Tasly's research anddevelopment performance has achieved remarkable results.This paper mainly adopts the case study method,which will explore the subject from the micro perspective of the enterprise,and analyze the number of patent applications and the number of patent grants through the unique internationalization model of Tasly Pharmaceutical Group Co.,Ltd.including overseas investment,international certification and technology introduction,patent quality,R&D investment and other indicators,and selected two comparable Chinese medicine listed companies and Tasly for comparative research.The research results show that overseas investment based on R&D and innovation can have a long-term incentive effect on independent innovation of enterprises compared with overseas investment based on capital operation alone,and will enhance the research and development stamina of enterprises.Taking Tasly as an example,traditional Chinese medicine enterprises in China can absorb the advanced technology of foreign pharmaceutical manufacturing industry through strategic international alliance,direct investment,cooperative R&D or technology introduction,and learn from the experience of overseas pharmaceutical companies in research and development of new drugs.Finally,through international certification,open overseas markets and realize the internationalization of Chinese medicine.